Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Corboy

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Neurology. Clinical Practice|August 15, 2018
Curbside consults join the telemedicine eraMarc R Nuwer, John R Corboy
Neurology. Clinical Practice|June 26, 2024
Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal LeukoencephalopathyAndrew B Wolf, John R Corboy
The Lancet. Neurology|September 8, 2019
Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosisEllen M Mowry, John R Corboy
Journal of Inflammation Research|November 19, 2011
Emerging therapies for treatment of multiple sclerosisJohn R Corboy, Augusto A Miravalle
Nature Reviews. Neurology|August 12, 2017
The tension between early diagnosis and misdiagnosis of multiple sclerosisAndrew J Solomon, John R Corboy
Neurology|August 20, 2008
Maintenance of certification: ready or not, here it comesJohn R Corboy, Mitchell S V Elkind
JAMA Neurology|November 20, 2023
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World ExperienceAndrew B Wolf, Enrique Alvarez, John R Corboy
Neurology|May 5, 2017
Baló concentric sclerosis evolving from apparent tumefactive demyelinationTodd A Hardy, John R Corboy, Brian G Weinshenker
Neurology|November 30, 2006
An adult case of leukoencephalopathy with intracranial calcifications and cystsJohn R Corboy, Judith Gault, B K Kleinschmidt-DeMasters
JAMA Neurology|April 19, 2021
Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?Eva M M Strijbis, Anne Kerbrat, John R Corboy
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Neurology. Clinical Practice|August 15, 2018
Curbside consults join the telemedicine eraMarc R Nuwer, John R Corboy
Neurology. Clinical Practice|June 26, 2024
Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal LeukoencephalopathyAndrew B Wolf, John R Corboy
The Lancet. Neurology|September 8, 2019
Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosisEllen M Mowry, John R Corboy
Journal of Inflammation Research|November 19, 2011
Emerging therapies for treatment of multiple sclerosisJohn R Corboy, Augusto A Miravalle
Nature Reviews. Neurology|August 12, 2017
The tension between early diagnosis and misdiagnosis of multiple sclerosisAndrew J Solomon, John R Corboy
Neurology|August 20, 2008
Maintenance of certification: ready or not, here it comesJohn R Corboy, Mitchell S V Elkind
JAMA Neurology|November 20, 2023
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World ExperienceAndrew B Wolf, Enrique Alvarez, John R Corboy
Neurology|May 5, 2017
Baló concentric sclerosis evolving from apparent tumefactive demyelinationTodd A Hardy, John R Corboy, Brian G Weinshenker
Neurology|November 30, 2006
An adult case of leukoencephalopathy with intracranial calcifications and cystsJohn R Corboy, Judith Gault, B K Kleinschmidt-DeMasters
JAMA Neurology|April 19, 2021
Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?Eva M M Strijbis, Anne Kerbrat, John R Corboy
Pageof 9